A role for zinc in pancreatic islet β‐cell cross‐talk with the α‐cell during hypoglycaemia (English)
- New search for: Robertson, R. P.
- New search for: Zhou, H.
- New search for: Slucca, M.
- New search for: Robertson, R. P.
- New search for: Zhou, H.
- New search for: Slucca, M.
In:
Diabetes, Obesity and Metabolism
;
13
;
106-111
;
2011
- Article (Journal) / Electronic Resource
-
Title:A role for zinc in pancreatic islet β‐cell cross‐talk with the α‐cell during hypoglycaemia
-
Contributors:
-
Published in:Diabetes, Obesity and Metabolism ; 13 ; 106-111
-
Publisher:
- New search for: Blackwell Publishing Ltd
-
Publication date:2011-10-01
-
Size:6 pages
-
ISSN:
-
DOI:
-
Type of media:Article (Journal)
-
Type of material:Electronic Resource
-
Language:English
-
Keywords:
-
Source:
Table of contents – Volume 13
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1
-
Early milestones in glucagon researchLefèbvre, P. J. et al. | 2011
- 1
-
11β‐Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitusHollis, G. / Huber, R. et al. | 2011
- 5
-
Basic helix‐loop‐helix transcription factors and enteroendocrine cell differentiationLi, H. J. / Ray, S. K. / Singh, N. K. / Johnston, B. / Leiter, A. B. et al. | 2011
- 7
-
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative reviewDeacon, C. F. et al. | 2011
- 13
-
Transcriptional regulation of α‐cell differentiationBramswig, N. C. / Kaestner, K. H. et al. | 2011
- 19
-
Discovery and characterization of taspoglutide, a novel analogue of human glucagon‐like peptide‐1, engineered for sustained therapeutic activity in type 2 diabetesDong, J. Z. / Shen, Y. / Zhang, J. / Tsomaia, N. / Mierke, D. F. / Taylor, J. E. et al. | 2011
- 21
-
Growth factor signalling in the regulation of α‐cell fateKawamori, D. / Akiyama, M. / Hu, J. / Hambro, B. / Kulkarni, R. N. et al. | 2011
- 26
-
Glucagon‐like peptide‐1(9‐36)amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet‐induced obese miceTomas, E. / Wood, J. A. / Stanojevic, V. / Habener, J. F. et al. | 2011
- 31
-
Glucagon gene expression in the endocrine pancreas: the role of the transcription factor Pax6 in α‐cell differentiation, glucagon biosynthesis and secretionGosmain, Y. / Cheyssac, C. / Heddad Masson, M. / Dibner, C. / Philippe, J. et al. | 2011
- 34
-
The role of small molecule GPR119 agonist, AS1535907, in glucose‐stimulated insulin secretion and pancreatic β‐cell functionYoshida, S. / Ohishi, T. / Matsui, T. / Tanaka, H. / Oshima, H. / Yonetoku, Y. / Shibasaki, M. et al. | 2011
- 39
-
Longevity of human islet α‐ and β‐cellsCnop, M. / Igoillo‐Esteve, M. / Hughes, S. J. / Walker, J. N. / Cnop, I. / Clark, A. et al. | 2011
- 42
-
Buccal spray insulin in subjects with impaired glucose tolerance: the prevoral studyPalermo, A. / Napoli, N. / Manfrini, S. / Lauria, A. / Strollo, R. / Pozzilli, P. et al. | 2011
- 47
-
In vivo conversion of adult α‐cells into β‐like cells: a new research avenue in the context of type 1 diabetesCourtney, M. / Pfeifer, A. / Al‐Hasani, K. / Gjernes, E. / Vieira, A. / Ben‐Othman, N. / Collombat, P. et al. | 2011
- 47
-
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjectsKasichayanula, S. / Liu, X. / Shyu, W. C. / Zhang, W. / Pfister, M. / Griffen, S. C. / Li, T. / LaCreta, F. P. / Boulton, D. W. et al. | 2011
- 53
-
Reprogramming gut and pancreas endocrine cells to treat diabetesTudurí, E. / Kieffer, T. J. et al. | 2011
- 55
-
Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trialsSchweizer, A. / Dejager, S. / Foley, J. E. / Shao, Q. / Kothny, W. et al. | 2011
- 60
-
Foetal proglucagon processing in relation to adult appetite control: lessons from a transplantable rat glucagonoma with severe anorexiaJensen, P. B. / Larsen, P. J. / Karlsen, C. / Jensen, H. I. / Holst, J. J. / Madsen, O. D. et al. | 2011
- 65
-
Safety and efficacy of linagliptin as add‐on therapy to metformin in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled studyTaskinen, M.‐R. / Rosenstock, J. / Tamminen, I. / Kubiak, R. / Patel, S. / Dugi, K. A. / Woerle, H.‐J. et al. | 2011
- 69
-
Incretin hormones and the expanding families of glucagon‐like sequences and their receptorsIrwin, D. M. / Prentice, K. J. et al. | 2011
- 75
-
Co‐administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interactionMorrow, L. / Hompesch, M. / Guthrie, H. / Chang, D. / Chatterjee, D. J. et al. | 2011
- 81
-
Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16‐week, randomized, double‐blind, active control trialYang, W. / Chen, L. / Ji, Q. / Liu, X. / Ma, J. / Tandon, N. / Bhattacharyya, A. / Kumar, A. / Kim, K.‐W. / Yoon, K.‐H. et al. | 2011
- 82
-
Brain glucose sensing and neural regulation of insulin and glucagon secretionThorens, B. et al. | 2011
- 89
-
Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetesSchroner, Z. / Javorsky, M. / Tkacova, R. / Klimcakova, L. / Dobrikova, M. / Habalova, V. / Kozarova, M. / Zidzik, J. / Rudikova, M. / Tkac, I. et al. | 2011
- 89
-
Regulation of glucagon secretion by incretinsHolst, J. J. / Christensen, M. / Lund, A. / de Heer, J. / Svendsen, B. / Kielgast, U. / Knop, F. K. et al. | 2011
- 92
-
Hot fat in a cool man: infrared thermography and brown adipose tissueLee, P. / Ho, K. K. Y. / Greenfield, J. R. et al. | 2011
- 94
-
News and ViewsIdris, Iskandar et al. | 2011
- 95
-
Regulation of glucagon secretion by glucose: paracrine, intrinsic or both?Walker, J. N. / Ramracheya, R. / Zhang, Q. / Johnson, P. R. V. / Braun, M. / Rorsman, P. et al. | 2011
- 97
-
Erratum| 2011
- 99
-
Pharmacological management of type 2 diabetes: the potential of incretin‐based therapiesCharbonnel, B. / Cariou, B. et al. | 2011
- 106
-
A role for zinc in pancreatic islet β‐cell cross‐talk with the α‐cell during hypoglycaemiaRobertson, R. P. / Zhou, H. / Slucca, M. et al. | 2011
- 112
-
Regulation of glucagon secretion by zinc: lessons from the β cell‐specific Znt8 knockout mouse modelHardy, A. B. / Serino, A. S. / Wijesekara, N. / Chimienti, F. / Wheeler, M. B. et al. | 2011
- 118
-
The potential role of glucagon‐like peptide‐1 or its analogues in enhancing glycaemic control in critically ill adult patientsCombes, J. / Borot, S. / Mougel, F. / Penfornis, A. et al. | 2011
- 118
-
Physiologic action of glucagon on liver glucose metabolismRamnanan, C. J. / Edgerton, D. S. / Kraft, G. / Cherrington, A. D. et al. | 2011
- 126
-
The role of dysregulated glucagon secretion in type 2 diabetesD'Alessio, D. et al. | 2011
- 130
-
Fuelling the athlete with type 1 diabetesGallen, I. W. / Hume, C. / Lumb, A. et al. | 2011
- 133
-
Optimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiencyFarhy, L. S. / McCall, A. L. et al. | 2011
- 137
-
Effects of colesevelam on LDL‐C, A1c and GLP‐1 levels in patients with type 1 diabetes: a pilot randomized double‐blind trialGarg, S. K. / Ritchie, P. J. / Moser, E. G. / Snell‐Bergeon, J. K. / Freson, B. J. / Hazenfield, R. M. et al. | 2011
- 144
-
Patient perspectives on once‐weekly medications for diabetesPolonsky, W. H. / Fisher, L. / Hessler, D. / Bruhn, D. / Best, J. H. et al. | 2011
- 144
-
Novel insight into glucagon receptor action: lessons from knockout and transgenic mouse modelsVuguin, P. M. / Charron, M. J. et al. | 2011
- 150
-
Minocycline completely reverses mechanical hyperalgesia in diabetic rats through microglia‐induced changes in the expression of the potassium chloride co‐transporter 2 (KCC2) at the spinal cordMorgado, C. / Pereira‐Terra, P. / Cruz, C. D. / Tavares, I. et al. | 2011
- 151
-
Metabolic impact of glucagon deficiencyHayashi, Y. et al. | 2011
- 158
-
The future of incretin‐based therapy: novel avenues—novel targetsAhrén, B. et al. | 2011
- 160
-
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double‐blind, non‐inferiority trialArechavaleta, R. / Seck, T. / Chen, Y. / Krobot, K. J. / O’Neill, E. A. / Duran, L. / Kaufman, K. D. / Williams‐Herman, D. / Goldstein, B. J. et al. | 2011
- 169
-
The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta‐analysisSingh‐Franco, D. / Perez, A. / Harrington, C. et al. | 2011
- 181
-
Phosphoprotein enriched in diabetes gene product (Ped/pea‐15) is increased in omental adipose tissue of women with the polycystic ovary syndrome: ex vivo regulation of ped/pea‐15 by glucose, insulin and metforminTan, B. K. / Chen, J. / Adya, R. / Randeva, H. S. et al. | 2011
- 185
-
Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY)Lindblad, U. / Lindberg, G. / Månsson, N.‐O. / Ranstam, J. / Tyrberg, M. / Jansson, S. / Lindwall, K. / Svärdh, M. / Kindmalm, L. / Melander, A. et al. | 2011
- 189
-
Regional fat changes following weight reduction from laparoscopic Roux‐en‐Y gastric bypass surgeryMiller, G. D. / Carr, J. J. / Fernandez, A. Z. et al. | 2011
- 193
-
Clinical evidence and mechanistic basis for vildagliptin's action when added to metforminAhrén, B. / Foley, J. E. / Bosi, E. et al. | 2011
- 204
-
Dietary prescriptions for the overweight patient: the potential benefits of low‐carbohydrate diets in insulin resistanceLee, M. W. / Fujioka, K. et al. | 2011
- 207
-
Liraglutide – overview of the preclinical and clinical data and its role in the treatment of type 2 diabetesDavies, M. J. / Kela, R. / Khunti, K. et al. | 2011
- 221
-
Effect of metformin on cardiovascular events and mortality: a meta‐analysis of randomized clinical trialsLamanna, C. / Monami, M. / Marchionni, N. / Mannucci, E. et al. | 2011
- 229
-
Brain functional magnetic resonance imaging response to glucose and fructose infusions in humansPurnell, J. Q. / Klopfenstein, B. A. / Stevens, A. A. / Havel, P. J. / Adams, S. H. / Dunn, T. N. / Krisky, C. / Rooney, W. D. et al. | 2011
- 235
-
Sodium tungstate regulates food intake and body weight through activation of the hypothalamic leptin pathwayAmigó‐Correig, M. / Barceló‐Batllori, S. / Piquer, S. / Soty, M. / Pujadas, G. / Gasa, R. / Bortolozzi, A. / Carmona, M. C. / Gomis, R. et al. | 2011
- 243
-
Chronic treatment with d‐chiro‐inositol prevents autonomic and somatic neuropathy in STZ‐induced diabetic miceFarias, V. X. / Macêdo, F. H. P. / Oquendo, M. B. / Tomé, A. R. / Báo, S. N. / Cintra, D. O. S. / Santos, C. F. / Albuquerque, A. A. C. / Heimark, D. B. / Larner, J. et al. | 2011
- 251
-
Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetesBolli, G. B. / Luzio, S. / Marzotti, S. / Porcellati, F. / Sert‐Langeron, C. / Charbonnel, B. / Zair, Y. / Owens, D. R. et al. | 2011
- 258
-
Effect of linagliptin monotherapy on glycaemic control and markers of β‐cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trialDel Prato, S. / Barnett, A. H. / Huisman, H. / Neubacher, D. / Woerle, H.‐J. / Dugi, K. A. et al. | 2011
- 268
-
Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trialHollander, P. / Raslova, K. / Skjøth, T. V. / Råstam, J. / Liutkus, J. F. et al. | 2011
- 276
-
Thiazolidinediones and congestive heart failure in veterans with type 2 diabetesToprani, A. / Fonseca, V. et al. | 2011
- 281
-
Oral magnesium supplementation reduces insulin resistance in non‐diabetic subjects – a double‐blind, placebo‐controlled, randomized trialMooren, F. C. / Krüger, K. / Völker, K. / Golf, S. W. / Wadepuhl, M. / Kraus, A. et al. | 2011
- 289
-
Diabetes is an inflammatory disease: evidence from traditional Chinese medicinesXie, W. / Du, L. et al. | 2011
- 302
-
Glucagon‐like peptide‐1‐based therapies and cardiovascular disease: looking beyond glycaemic controlAnagnostis, P. / Athyros, V. G. / Adamidou, F. / Panagiotou, A. / Kita, M. / Karagiannis, A. / Mikhailidis, D. P. et al. | 2011
- 313
-
Therapies for diabetic dyslipidaemiaBell, D. S. H. / Al Badarin, F. / O’Keefe, J. H. Jr et al. | 2011
- 326
-
Taspoglutide, a novel human once‐weekly GLP‐1 analogue, protects pancreatic β‐cells in vitro and preserves islet structure and function in the Zucker diabetic fatty rat in vivoUhles, S. / Wang, H. / Bénardeau, A. / Prummer, M. / Brecheisen, M. / Sewing, S. / Tobalina, L. / Bosco, D. / Wollheim, C. B. / Migliorini, C. et al. | 2011
- 337
-
Effects of chronic administration of alogliptin on the development of diabetes and β‐cell function in high fat diet/streptozotocin diabetic miceZhang, X. / Wang, Z. / Huang, Y. / Wang, J. et al. | 2011
- 348
-
Liraglutide, a once‐daily human glucagon‐like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetesGarber, A. / Henry, R. R. / Ratner, R. / Hale, P. / Chang, C. T. / Bode, B. et al. | 2011
- 357
-
Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–glucose co‐transporter type 2, in Japanese subjects without and with type 2 diabetes mellitusKasichayanula, S. / Chang, M. / Hasegawa, M. / Liu, X. / Yamahira, N. / LaCreta, F. P. / Imai, Y. / Boulton, D. W. et al. | 2011
- 366
-
Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetesTremblay, A. J. / Lamarche, B. / Deacon, C. F. / Weisnagel, S. J. / Couture, P. et al. | 2011
- 374
-
Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetesBunck, M. C. / Eliasson, B. / Cornér, A. / Heine, R. J. / Shaginian, R. M. / Taskinen, M.‐R. / Yki‐Järvinen, H. / Smith, U. / Diamant, M. et al. | 2011
- 378
-
Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase‐4 activity in obese patients with type 2 diabetesAlam, M. L. / Van der Schueren, B. J. / Ahren, B. / Wang, G. C. / Swerdlow, N. J. / Arias, S. / Bose, M. / Gorroochurn, P. / Teixeira, J. / McGinty, J. et al. | 2011
- 382
-
Exercise training improves physical fitness and vascular function in children with type 1 diabetesSeeger, J. P. H. / Thijssen, D. H. J. / Noordam, K. / Cranen, M. E. C. / Hopman, M. T. E. / Nijhuis‐van der Sanden, M. W. G. et al. | 2011
- 385
-
Pharmacotherapy for overweight/obesity in ethnic minorities and White Caucasians: a systematic review and meta‐analysisOsei‐Assibey, G. / Adi, Y. / Kyrou, I. / Kumar, S. / Matyka, K. et al. | 2011
- 394
-
An overview of once‐weekly glucagon‐like peptide‐1 receptor agonists—available efficacy and safety data and perspectives for the futureMadsbad, S. / Kielgast, U. / Asmar, M. / Deacon, C. F. / Torekov, S. S. / Holst, J. J. et al. | 2011
- 408
-
Pulmonary delivery of peptide YY for food intake suppression and reduced body weight gain in ratsNadkarni, P. P. / Costanzo, R. M. / Sakagami, M. et al. | 2011
- 418
-
The effects of LY2189265, a long‐acting glucagon‐like peptide‐1 analogue, in a randomized, placebo‐controlled, double‐blind study of overweight/obese patients with type 2 diabetes: the EGO studyUmpierrez, G. E. / Blevins, T. / Rosenstock, J. / Cheng, C. / Anderson, J. H. / Bastyr, E. J. III / for the EGO Study Group et al. | 2011
- 426
-
A 5‐week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long‐acting glucagon‐like peptide‐1 analogue, in patients with type 2 diabetesBarrington, P. / Chien, J. Y. / Showalter, H. D. H. / Schneck, K. / Cui, S. / Tibaldi, F. / Ellis, B. / Hardy, T. A. et al. | 2011
- 434
-
LY2189265, a long‐acting glucagon‐like peptide‐1 analogue, showed a dose‐dependent effect on insulin secretion in healthy subjectsBarrington, P. / Chien, J. Y. / Tibaldi, F. / Showalter, H. D. H. / Schneck, K. / Ellis, B. et al. | 2011
- 439
-
Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes—a randomized controlled trialEsposito, K. / Maiorino, M. I. / Di Palo, C. / Gicchino, M. / Petrizzo, M. / Bellastella, G. / Saccomanno, F. / Giugliano, D. et al. | 2011
- 446
-
JTT‐130, a novel intestine‐specific inhibitor of microsomal triglyceride transfer protein, suppresses high fat diet‐induced obesity and glucose intolerance in Sprague‐Dawley ratsHata, T. / Mera, Y. / Tadaki, H. / Kuroki, Y. / Kawai, T. / Ohta, T. / Kakutani, M. et al. | 2011
- 455
-
A new, highly selective murine peroxisome proliferator‐activated receptor δ agonist increases responsiveness to thermogenic stimuli and glucose uptake in skeletal muscle in obese miceNgala, R. A. / Stocker, C. J. / Roy, A. G. / Hislop, D. / Wargent, E. / Bell, R. / Hassall, D. G. / Harling, J. D. / Billin, A. N. / Willson, T. M. et al. | 2011
- 465
-
Inhibition of NADPH oxidase alleviates experimental diabetes‐induced myocardial contractile dysfunctionRoe, N. D. / Thomas, D. P. / Ren, J. et al. | 2011
- 474
-
In support of an early intensive treatment of type 2 diabetes and not necessarily of early polypharmacyCzupryniak, L. / Szymańska‐Garbacz, E. / Pawłowski, M. / Saryusz‐Wolska, M. / Loba, J. et al. | 2011
- 479
-
Interventions in primary care to improve cardiovascular risk factors and glycated haemoglobin (HbA1c) levels in patients with diabetes: a systematic reviewSeitz, P. / Rosemann, T. / Gensichen, J. / Huber, C. A. et al. | 2011
- 490
-
Pharmaceutical interventions for obesity: a public health perspectiveCaveney, E. / Caveney, B. J. / Somaratne, R. / Turner, J. R. / Gourgiotis, L. et al. | 2011
- 498
-
Effects of an 11β‐hydroxysteroid dehydrogenase type 1 inhibitor, MK‐0916, in patients with type 2 diabetes mellitus and metabolic syndromeFeig, P. U. / Shah, S. / Hermanowski‐Vosatka, A. / Plotkin, D. / Springer, M. S. / Donahue, S. / Thach, C. / Klein, E. J. / Lai, E. / Kaufman, K. D. et al. | 2011
- 505
-
Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetesShah, P. K. / Mudaliar, S. / Chang, A. R. / Aroda, V. / Andre, M. / Burke, P. / Henry, R. R. et al. | 2011
- 511
-
Insulin dose–response studies in severely insulin‐resistant type 2 diabetes—evidence for effectiveness of very high insulin dosesKampmann, U. / Hoeyem, P. / Mengel, A. / Schmitz, O. / Rungby, J. / Orskov, L. / Møller, N. et al. | 2011
- 517
-
Association of β‐2 adrenergic agonist and corticosteroid injection in the treatment of lipomasRedman, L. M. / Moro, C. / Dobak, J. / Yu, Y. / Guillot, T. S. / Greenway, F. L. et al. | 2011
- 523
-
Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairmentNowicki, M. / Rychlik, I. / Haller, H. / Warren, M. L. / Suchower, L. / Gause‐Nilsson, I. / for the D1680C00007 Investigators et al. | 2011
- 533
-
Telmisartan, a dual ARB/partial PPAR‐γ agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetesGoyal, S. N. / Bharti, S. / Bhatia, J. / Nag, T. C. / Ray, R. / Arya, D. S. et al. | 2011
- 542
-
The oral DPP‐4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitusForst, T. / Uhlig‐Laske, B. / Ring, A. / Ritzhaupt, A. / Graefe‐Mody, U. / Dugi, K. A. et al. | 2011
- 551
-
Adipocytes express a functional system for serotonin synthesis, reuptake and receptor activationStunes, A. K. / Reseland, J. E. / Hauso, Ø. / Kidd, M. / Tømmerås, K. / Waldum, H. L. / Syversen, U. / Gustafsson, B. I. et al. | 2011
- 559
-
A cohort study of acute pancreatitis in relation to exenatide useDore, D. D. / Bloomgren, G. L. / Wenten, M. / Hoffman, C. / Clifford, C. R. / Quinn, S. G. / Braun, D. K. / Noel, R. A. / Seeger, J. D. et al. | 2011
- 567
-
Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeksPfützner, A. / Paz‐Pacheco, E. / Allen, E. / Frederich, R. / Chen, R. / for the CV181039 Investigators et al. | 2011
- 577
-
Emerging role of thiamine therapy for prevention and treatment of early‐stage diabetic nephropathyRabbani, N. / Thornalley, P. J. et al. | 2011
- 584
-
Therapeutic potential of panduratin A, LKB1‐dependent AMP‐activated protein kinase stimulator, with activation of PPARα/δ for the treatment of obesityKim, D. / Lee, M.‐S. / Jo, K. / Lee, K.‐E. / Hwang, J.‐K. et al. | 2011
- 594
-
Dipeptidyl peptidase‐4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta‐analysis of randomized controlled trialsEsposito, K. / Cozzolino, D. / Bellastella, G. / Maiorino, M. I. / Chiodini, P. / Ceriello, A. / Giugliano, D. et al. | 2011
- 604
-
Saxagliptin, a potent, selective inhibitor of DPP‐4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjectsPatel, C. G. / Kornhauser, D. / Vachharajani, N. / Komoroski, B. / Brenner, E. / Handschuh del Corral, M. / Li, L. / Boulton, D. W. et al. | 2011
- 615
-
Lipid‐altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trialsLeiter, L. A. / Betteridge, D. J. / Farnier, M. / Guyton, J. R. / Lin, J. / Shah, A. / Johnson‐Levonas, A. O. / Brudi, P. et al. | 2011
- 629
-
JTT‐130, a novel intestine‐specific inhibitor of microsomal triglyceride transfer protein, ameliorates impaired glucose and lipid metabolism in Zucker diabetic fatty ratsHata, T. / Mera, Y. / Kawai, T. / Ishii, Y. / Kuroki, Y. / Kakimoto, K. / Ohta, T. / Kakutani, M. et al. | 2011
- 639
-
Dose response of subcutaneous GLP‐1 infusion in patients with type 2 diabetesTorekov, S. S. / Kipnes, M. S. / Harley, R. E. / Holst, J. J. / Ehlers, M. R. et al. | 2011
- 644
-
The effect of initial therapy with the fixed‐dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitusReasner, C. / Olansky, L. / Seck, T. L. / Williams‐Herman, D. E. / Chen, M. / Terranella, L. / Johnson‐Levonas, A. O. / Kaufman, K. D. / Goldstein, B. J. et al. | 2011
- 653
-
Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double‐blind, placebo‐controlled studyGomis, R. / Espadero, R.‐M. / Jones, R. / Woerle, H. J. / Dugi, K. A. et al. | 2011
- 662
-
Rotational co‐culture of clonal β‐cells with endothelial cells: effect of PPAR‐γ agonism in vitro on insulin and VEGF secretionPaget, M. B. / Murray, H. E. / Bailey, C. J. / Flatt, P. R. / Downing, R. et al. | 2011
- 669
-
Canagliflozin, a novel inhibitor of sodium glucose co‐transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjectsSha, S. / Devineni, D. / Ghosh, A. / Polidori, D. / Chien, S. / Wexler, D. / Shalayda, K. / Demarest, K. / Rothenberg, P. et al. | 2011
- 677
-
A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitationsEvans, M. / Schumm‐Draeger, P. M. / Vora, J. / King, A. B. et al. | 2011
- 685
-
Future of GPR109A agonists in the treatment of dyslipidaemiaWanders, D. / Judd, R. L. et al. | 2011
- 692
-
Current therapeutic strategies in non‐alcoholic fatty liver diseaseDowman, J. K. / Armstrong, M. J. / Tomlinson, J. W. / Newsome, P. N. et al. | 2011
- 703
-
Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide auditThong, K. Y. / Jose, B. / Sukumar, N. / Cull, M. L. / Mills, A. P. / Sathyapalan, T. / Shafiq, W. / Rigby, A. S. / Walton, C. / Ryder, R. E. J. et al. | 2011
- 711
-
Two‐year glycaemic control and healthcare expenditures following initiation of insulin glargine versus neutral protamine Hagedorn insulin in type 2 diabetesRhoads, G. G. / Dain, M. P. / Zhang, Q. / Kennedy, L. et al. | 2011
- 718
-
Optimized glycaemic control achieved with add‐on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargineFadini, G. P. / de Kreutzenberg, S. V. / Mariano, V. / Boscaro, E. / Bertolini, F. / Mancuso, P. / Quarna, J. / Marescotti, M. / Agostini, C. / Tiengo, A. et al. | 2011
- 726
-
Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorderHardy, T. A. / Henry, R. R. / Forrester, T. D. / Kryzhanovskaya, L. A. / Campbell, G. M. / Marks, D. M. / Mudaliar, S. et al. | 2011
- 736
-
α‐Lipoic acid normalizes nociceptive neuronal activity at the spinal cord of diabetic ratsMorgado, C. / Pereira‐Terra, P. / Tavares, I. et al. | 2011
- 742
-
Dual modulation of GIP and glucagon action by the low molecular weight compound 4‐hydroxybenzoic acid 2‐bromobenzylidene hydrazideFranklin, Z. J. / McDonnell, B. / Montgomery, I. A. / Flatt, P. R. / Irwin, N. et al. | 2011
- 750
-
JSH‐23 targets nuclear factor‐kappa B and reverses various deficits in experimental diabetic neuropathy: effect on neuroinflammation and antioxidant defenceKumar, A. / Negi, G. / Sharma, S. S. et al. | 2011
- 759
-
High‐density lipoprotein‐cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactiveFerrannini, E. / Betteridge, D. J. / Dormandy, J. A. / Charbonnel, B. / Wilcox, R. G. / Spanheimer, R. / Erdmann, E. / DeFronzo, R. A. / Laakso, M. et al. | 2011
- 765
-
Treatment intensification in patients with type 2 diabetes who failed metformin monotherapyFu, A. Z. / Qiu, Y. / Davies, M. J. / Radican, L. / Engel, S. S. et al. | 2011
- 770
-
Effect of a high‐fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjectsKasichayanula, S. / Liu, X. / Zhang, W. / Pfister, M. / Reele, S. B. / Aubry, A.‐F. / LaCreta, F. P. / Boulton, D. W. et al. | 2011
- 775
-
Mechanisms of action of the dipeptidyl peptidase‐4 inhibitor vildagliptin in humansAhrén, B. / Schweizer, A. / Dejager, S. / Villhauer, E. B. / Dunning, B. E. / Foley, J. E. et al. | 2011
- 784
-
New approaches to the treatment of diabetic retinopathyPorta, M. / Maldari, P. / Mazzaglia, F. et al. | 2011
- 791
-
Glitazone‐like action of glimepiride and glibenclamide in primary human adipocytesMayer, P. / Haas, B. / Celner, J. / Enzmann, H. / Pfeifer, A. et al. | 2011
- 800
-
Triple oral fixed‐dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study‐II)Bell, D. S. H. / Dharmalingam, M. / Kumar, S. / Sawakhande, R. B. et al. | 2011
- 806
-
A randomized‐controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose–lipid control in type 2 diabetesKong, A. P. S. / Yamasaki, A. / Ozaki, R. / Saito, H. / Asami, T. / Ohwada, S. / Ko, G. T. C. / Wong, C. K. / Leung, G. T. C. / Lee, K. F. et al. | 2011
- 814
-
An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemiaFonseca, V. / Gill, J. / Zhou, R. / Leahy, J. et al. | 2011
- 823
-
Weight and glycaemic control in type 2 diabetes: what is the outcome of insulin initiation?Watson, L. / Wilson, B. P. / Alsop, J. / Kumar, S. et al. | 2011
- 832
-
Comparison of insulins detemir and glargine: effects on glucose disposal, hepatic glucose release and the central nervous systemMoore, M. C. / Smith, M. S. / Turney, M. K. / Boysen, S. / Williams, P. E. et al. | 2011
- 841
-
A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agentsOlansky, L. / Reasner, C. / Seck, T. L. / Williams‐Herman, D. E. / Chen, M. / Terranella, L. / Mehta, A. / Kaufman, K. D. / Goldstein, B. J. et al. | 2011
- 850
-
Effects of saxagliptin on β‐cell stimulation and insulin secretion in patients with type 2 diabetesHenry, R. R. / Smith, S. R. / Schwartz, S. L. / Mudaliar, S. R. / Deacon, C. F. / Holst, J. J. / Duan, R. Y. / Chen, R. S. / List, J. F. et al. | 2011
- 859
-
Differentiating short‐ and long‐term effects of diet in the obese mouse using 1H‐nuclear magnetic resonance metabolomicsDuggan, G. E. / Hittel, D. S. / Hughey, C. C. / Weljie, A. / Vogel, H. J. / Shearer, J. et al. | 2011
- 863
-
Dissociated incretin hormone response to protein versus fat ingestion in obese subjectsLindgren, O. / Carr, R. D. / Holst, J. J. / Deacon, C. F. / Ahrén, B. et al. | 2011
- 869
-
Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetesChaudhuri, A. / Dandona, P. et al. | 2011
- 880
-
Why does quick‐release bromocriptine decrease cardiac events?Bell, D. S. H. et al. | 2011
- 885
-
Lentiviral vector‐mediated knockdown of SOCS3 in the hypothalamus protects against the development of diet‐induced obesity in ratsLiu, Z.‐J. / Bian, J. / Zhao, Y.‐L. / Zhang, X. / Zou, N. / Li, D. et al. | 2011
- 893
-
Metabolic effects of muraglitazar in type 2 diabetic subjectsFernandez, M. / Gastaldelli, A. / Triplitt, C. / Hardies, J. / Casolaro, A. / Petz, R. / Tantiwong, P. / Musi, N. / Cersosimo, E. / Ferrannini, E. et al. | 2011
- 903
-
Cannabinoid receptor agonists and antagonists stimulate insulin secretion from isolated human islets of LangerhansLi, C. / Bowe, J. E. / Huang, G. C. / Amiel, S. A. / Jones, P. M. / Persaud, S. J. et al. | 2011
- 911
-
A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet‐induced obese ratsFeigh, M. / Henriksen, K. / Andreassen, K. V. / Hansen, C. / Henriksen, J. E. / Beck‐Nielsen, H. / Christiansen, C. / Karsdal, M. A. et al. | 2011
- 921
-
Cardiovascular outcomes associated with a new once‐weekly GLP‐1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysisPeskin, B. R. / Shcheprov, A. V. / Boye, K. S. / Bruce, S. / Maggs, D. G. / Gaebler, J. A. et al. | 2011
- 928
-
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trialStrojek, K. / Yoon, K. H. / Hruba, V. / Elze, M. / Langkilde, A. M. / Parikh, S. et al. | 2011
- 939
-
Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase‐4 inhibitor linagliptinGraefe‐Mody, U. / Friedrich, C. / Port, A. / Ring, A. / Retlich, S. / Heise, T. / Halabi, A. / Woerle, H.‐J. et al. | 2011
- 947
-
Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24‐week randomized placebo‐controlled trialLukashevich, V. / Schweizer, A. / Shao, Q. / Groop, P.‐H. / Kothny, W. et al. | 2011
- 955
-
Vitamin A improves insulin sensitivity by increasing insulin receptor phosphorylation through protein tyrosine phosphatase 1B regulation at early age in obese rats of WNIN/Ob strainJeyakumar, S. M. / Vijaya Kumar, P. / Giridharan, N. V. / Vajreswari, A. et al. | 2011
- 959
-
Exercise training increases adipose tissue GLUT4 expression in patients with type 2 diabetesHussey, S. E. / McGee, S. L. / Garnham, A. / Wentworth, J. M. / Jeukendrup, A. E. / Hargreaves, M. et al. | 2011
- 963
-
Phentermine therapy for obesity does not elevate blood pressureHendricks, E. J. / Rothman, R. B. et al. | 2011
- 965
-
Glucagon antagonism as a potential therapeutic target in type 2 diabetesBagger, J. I. / Knop, F. K. / Holst, J. J. / Vilsbøll, T. et al. | 2011
- 972
-
Glucagon‐like peptide‐1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta‐analysis of clinical trialsWang, Y. / Li, L. / Yang, M. / Liu, H. / Boden, G. / Yang, G. et al. | 2011
- 982
-
Effects of exenatide twice daily versus sitagliptin on 24‐h glucose, glucoregulatory and hormonal measures: a randomized, double‐blind, crossover studyBerg, J. K. / Shenouda, S. K. / Heilmann, C. R. / Gray, A. L. / Holcombe, J. H. et al. | 2011
- 990
-
GLP‐1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic miceJolivalt, C. G. / Fineman, M. / Deacon, C. F. / Carr, R. D. / Calcutt, N. A. et al. | 2011
- 1001
-
Short‐term metabolic effects of prednisone administration in healthy subjectsKauh, E. A. / Mixson, L. A. / Shankar, S. / McCarthy, J. / Maridakis, V. / Morrow, L. / Heinemann, L. / Ruddy, M. K. / Herman, G. A. / Kelley, D. E. et al. | 2011
- 1008
-
Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta‐analysisPontiroli, A. E. / Miele, L. / Morabito, A. et al. | 2011
- 1020
-
Effects of initiation and titration of a single pre‐prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6‐month ‘proof‐of‐concept' studyOwens, D. R. / Luzio, S. D. / Sert‐Langeron, C. / Riddle, M. C. et al. | 2011
- 1028
-
Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial with an open‐label long‐term extension studyKaku, K. / Itayasu, T. / Hiroi, S. / Hirayama, M. / Seino, Y. et al. | 2011
- 1036
-
A randomized, parallel group, double‐blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long‐term glycaemic control and bone mineral density after 80 weeks of treatment in drug‐naïve type 2 diabetes mellitus patientsBorges, J. L. C. / Bilezikian, J. P. / Jones‐Leone, A. R. / Acusta, A. P. / Ambery, P. D. / Nino, A. J. / Grosse, M. / Fitzpatrick, L. A. / Cobitz, A. R. et al. | 2011
- 1047
-
Comparative long‐term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20–40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemiaGumprecht, J. / Gosho, M. / Budinski, D. / Hounslow, N. et al. | 2011
- 1056
-
Effects of a long‐acting GLP‐1 mimetic (PF‐04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitusGustavson, S. M. / Chen, D. / Somayaji, V. / Hudson, K. / Baltrukonis, D. J. / Singh, J. / Boyden, T. L. / Calle, R. A. et al. | 2011
- 1063
-
Does intentional weight loss reduce cancer risk?Byers, T. / Sedjo, R. L. et al. | 2011
- 1073
-
Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?Rensing, K. L. / Reuwer, A. Q. / Arsenault, B. J. / von der Thüsen, J. H. / Hoekstra, J. B. L. / Kastelein, J. J. P. / Twickler, Th. B. et al. | 2011
- 1088
-
Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52‐week, randomized, double‐blind, active‐controlled, parallel‐group studyBosi, E. / Ellis, G. C. / Wilson, C. A. / Fleck, P. R. et al. | 2011
- 1097
-
Metformin opposes impaired AMPK and SIRT1 function and deleterious changes in core clock protein expression in white adipose tissue of genetically‐obese db/db miceCaton, P. W. / Kieswich, J. / Yaqoob, M. M. / Holness, M. J. / Sugden, M. C. et al. | 2011
- 1105
-
Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptideMack, C. M. / Smith, P. A. / Athanacio, J. R. / Xu, K. / Wilson, J. K. / Reynolds, J. M. / Jodka, C. M. / Lu, M. G. W. / Parkes, D. G. et al. | 2011
- 1114
-
Tigerinin‐1R: a potent, non‐toxic insulin‐releasing peptide isolated from the skin of the Asian frog, Hoplobatrachus rugulosusOjo, O. O. / Abdel‐Wahab, Y. H. A. / Flatt, P. R. / Mechkarska, M. / Conlon, J. M. et al. | 2011
- 1123
-
Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky ratsZhao, M. / Li, Y. / Wang, J. / Ebihara, K. / Rong, X. / Hosoda, K. / Tomita, T. / Nakao, K. et al. | 2011
- 1130
-
Differential response between diabetes and stress‐induced hyperglycaemia to algorithmic use of detemir and flexible mealtime aspart among stable postcardiac surgery patients requiring intravenous insulinDungan, K. / Hall, C. / Schuster, D. / Osei, K. et al. | 2011
- 1136
-
Differences in insulin treatment satisfaction following randomized addition of biphasic, prandial or basal insulin to oral therapy in type 2 diabetesFarmer, A. J. / Oke, J. / Stevens, R. / Holman, R. R. et al. | 2011
- 1142
-
Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal‐bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open‐label study (NCT00135096)Ratner, R. / Wynne, A. / Nakhle, S. / Brusco, O. / Vlajnic, A. / Rendell, M. et al. | 2011
- 1149
-
Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal‐bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open‐label trialKoivisto, V. / Cleall, S. / Pontiroli, A. E. / Giugliano, D. et al. | 2011
- v
-
Long in the shade, glucagon re‐occupies centre courtHenquin, J.‐C. / Accili, D. / Ahrén, B. / Boitard, C. / Seino, S. / Cerasi, E. et al. | 2011